Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: A preliminary randomized controlled study

Photomedicine and Laser Surgery

Volumn 28, Issue 5, 2010, Pages 679-684

  Asawanonda, Pravit ^a   Klahan, Siri On ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECT; DIGITAL PHOTOGRAPHY; IN-DEGREE; MONO-THERAPY; NARROW BANDS; PHOTOTHERAPY; SENSITIVE AREA; TOPICAL TREATMENTS; TREATMENT GROUP; UV TREATMENT;

GAS LASERS;

EXCIMER LASERS;

CURCUMIN; DRUG DERIVATIVE; EMOLLIENT AGENT; TETRAHYDROCURCUMIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NONPARAMETRIC TEST; PHOTOTHERAPY; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SKIN PIGMENTATION; TREATMENT OUTCOME; VITILIGO;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; COMBINED MODALITY THERAPY; CURCUMIN; DOUBLE-BLIND METHOD; EMOLLIENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIATION DOSAGE; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; SKIN PIGMENTATION; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; VITILIGO;

EID: 78751670770     PISSN: 15495418     EISSN: None     Source Type: Journal    
DOI: 10.1089/pho.2009.2637     Document Type: Article

References (48)

1. Pari, L., Tewas, D., and Eckel, J. (2008). Role of curcumin in health and disease. Arch. Physiol. Biochem. 114, 127-149.
2. Ali, R.E., and Rattan, S.I. (2006). Curcumin's biphasic hormetic response on proteasome activity and heat-shock protein synthesis in human keratinocytes. Ann. N. Y. Acad. Sci. 1067, 394-399.
3. Gautam, S.C., Gao, X., and Dulchavsky, S. (2007). Immunomodulation by curcumin. Adv. Exp. Med. Biol. 595, 321-341.
4. Chainani-Wu, N. (2003). Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J. Altern. Complement. Med. 9, 161-168.
5. Menon, V.P., and Sudheer, A.R. (2007). Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol. 595, 105-125.
6. Jagetia, G.C. (2007). Radioprotection and radiosensitization by curcumin. Adv. Exp. Med. Biol. 595, 301-320.
7. Thangapazham, R.L., Sharma, A., and Maheshwari, R.K. (2007). Beneficial role of curcumin in skin diseases. Adv. Exp. Med. Biol. 595, 343-357.
8. Miriyala, S., Panchatcharam, M., and Rengarajulu, P. (2007). Cardioprotective effects of curcumin. Adv. Exp. Med. Biol. 595, 359-377.
9. Araujo, C.C., and Leon, L.L. (2001). Biological activities of Curcuma longa L. Mem. Inst. Oswaldo Cruz 96, 723-728.
10. Strimpakos, A.S., and Sharma, R.A. (2008). Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signal. 10, 511-545.
11. Aggarwal, B.B., Kumar, A., and Bharti, A.C. (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 23, 363-398.
12. Kuttan, G., Kumar, K.B., Guruvayoorappan, C., and Kuttan, R. (2007). Antitumor, anti-invasion, and antimetastatic effects of curcumin. Adv. Exp. Med. Biol. 595, 173-184.
13. Surh, Y.J., and Chun, K.S. (2007). Cancer chemopreventive effects of curcumin. Adv. Exp. Med. Biol. 595, 149-172.
14. Cole, G.M., Teter, B., and Frautschy, S.A. (2007). Neuroprotective effects of curcumin. Adv. Exp. Med. Biol. 595, 197-212.
15. Hsu, C.H., and Cheng, A.L. (2007). Clinical studies with curcumin. Adv. Exp. Med. Biol. 595, 471-480.
16. Anand, P., Kunnumakkara, A.B., Newman, R.A., and Aggarwal, B.B. (2007). Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807-818.
17. Sugiyama, Y., Kawakishi, S., and Osawa, T. (1996). Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin. Biochem. Pharmacol. 52, 519-525.
18. Khopde, S.M., Priyadarsini, K.I., Guha, S.N., Satav, J.G., Venkatesan, P., and Rao, M.N. (2000). Inhibition of radiation-induced lipid peroxidation by tetrahydrocurcumin: Possible mechanisms by pulse radiolysis. Biosci. Biotechnol. Biochem. 64, 503-509.
19. Kadoma, Y., and Fujisawa, S. (2007). Comparative radicalscavenging activity of curcumin and tetrahydrocurcumin with thiols as measured by the induction period method. In Vivo 21, 979-982.
20. Pari, L., and Murugan, P. (2007). Tetrahydrocurcumin prevents brain lipid peroxidation in streptozotocin-induced diabetic rats. J. Med. Food 10, 323-329.
21. Arunothayanun, P., Wirachwong, P., Burananon, V., et al. (2005).Development of tetrahydrocurcuminoid liposomes as an ingredient for cosmetic products. Proc 7th Scientific Conference of the Asian Society of Cosmetic Scientists. pp. 51.1-7.
22. Asawanonda, P., Charoenlap, M., and Korkij, W. (2006). Treatment of localized vitiligo with targeted broadband UVB phototherapy: a pilot study. Photodermatol. Photoimmunol. Photomed. 22, 133-136.
23. Asawanonda, P., Kijluakiat, J., Korkij, W., and Sindhupak, W. (2008). Targeted broadband UVB phototherapy produces similar responses to targeted narrowband UVB for vitiligo: a randomized, double-blind study. Acta. Derm. Venereol. 88, 376-381.
24. Klahan, S., and Asawanonda, P. (2009). Topical tacrolimus enhances the repigmentation capacity of targeted narrowband UVB phototherapy in the treatment of vitiligo: a randomized, controlled study. Clin. Exp. Dermatol. 34: e1029-e1030.
25. Taneja, A., Trehan, M., and Taylor, C.R. (2003). 308-nm excimer laser for the treatment of localized vitiligo. Int. J. Dermatol. 42, 658-662.
26. Baltas, E., Nagy, P., Bonis B., et al. (2001). Repigmentation of localized vitiligo with the xenon chloride laser. Br. J. Dermatol. 144, 1266-1267.
27. Baltas, E., Csoma, Z., Ignacz, F., Dobozy, A., and Kemeny, L. (2002). Treatment of vitiligo with the 308-nm xenon chloride excimer laser. Arch. Dermatol. 138, 1619-1620.
28. Spencer, J.M., Nossa, R., and Ajmeri, J. (2002). Treatment of vitiligo with the 308-nm excimer laser: A pilot study. J. Am. Acad. Dermatol. 46, 727-731.
29. Ostovari, N., Passeron, T., Zakaria, W., et al. (2004). Treatment of vitiligo by 308-nm excimer laser: an evaluation of variables affecting treatment response. Lasers Surg. Med. 35, 152-156.
30. Esposito, M., Soda, R., Costanzo, A., and Chimenti, S. (2004). Treatment of vitiligo with the 308nm excimer laser. Clin. Exp. Dermatol. 29, 133-137.
31. Hofer, A., Hassan, A.S., Legat, F.J., Kerl, H., and Wolf, P. (2005). Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. Br. J. Dermatol. 152, 981-985.
32. Passeron, T., and Ortonne, J.P. (2006). Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin. Dermatol. 24, 33-42.
33. Hofer,A.,Hassan,A.S., Legat, F.J., Kerl,H., andWolf, P. (2006). The efficacy of excimer laser (308nm) for vitiligo at different body sites. J. Eur. Acad. Dermatol. Venereol. 20, 558-564.
34. Hadi, S., Tinio, P., Al-Ghaithi, K., et al. (2006). Treatment of vitiligo using the 308-nm excimer laser. Photomed. Laser Surg. 24, 354-357.
35. Hong, S.B., Park, H.H., and Lee, M.H. (2005). Short-term effects of 308-nm xenon-chloride excimer laser and narrowband ultraviolet B in the treatment of vitiligo: a comparative study. J. Korean Med. Sci. 20, 273-278.
36. Hadi, S.M., Spencer, J.M., and Lebwohl, M. (2004). The use of the 308-nm excimer laser for the treatment of vitiligo. Dermatol. Surg. 30, 983-986.
37. Choi, K.H., Park, J.H., and Ro, Y.S. (2004). Treatment of vitiligo with 308-nm xenon-chloride excimer laser: therapeutic efficacy of different initial doses according to treatment areas. J. Dermatol. 31, 284-292.
38. Greve, B., Raulin, C., and Fischer, E. (2006). Excimer laser treatment of vitiligo-critical retrospective assessment of own results and literature overview. J. Dtsch. Dermatol. Ges. 4, 32-40.
39. Tanghetti, E.A., and Gillis, P.R. (2003). Clinical evaluation of B Clear and Protopic treatment for vitiligo [abstract]. Lasers Surg. Med. 32, 7.
40. Leone, G., Iacovelli, P., Paro Vidolin, A., and Picardo, M. (2003). Monochromatic excimer light 308nm in the treatment of vitiligo: a pilot study. J. Eur. Acad. Dermatol. Venereol. 17, 531-537.
41. Casacci, M., Thomas, P., Pacifico, A., Bonnevalle, A., Paro Vidolin, A., and Leone, G. (2007). Comparison between 308- nm monochromatic excimer light and narrowband UVB phototherapy (311-313 nm) in the treatment of vitiligo - a multicentre controlled study. J. Eur. Acad. Dermatol. Venereol. 21, 956-963.
42. Passeron, T., Ostovari, N., Zakaria, W., et al. (2004). Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch. Dermatol. 140, 1065-1069.
43. Kawalek, A.Z., Spencer, J.M., and Phelps, R.G. (2004). Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol. Surg. 30, 130-135.
44. Lotti, T., Buggiani, G., Troiano, M., et al. (2008). Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol. Ther. 21, S20-26.
45. Ostovari, N., Passeron, T., Lacour, J.P., and Ortonne, J.P. (2006). Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. Arch. Dermatol. 142, 252-253.
46. Schallreuter, K.U., and Rokos, H. (2006). Turmeric (curcumin): a widely used curry ingredient, can contribute to oxidative stress in Asian patients with acute vitiligo. Indian J. Dermatol. Venereol. Leprol. 72, 57-59.
47. Gonzalez, S., Pathak, M.A., Cuevas, J., Villarrubia, V.G., and Fitzpatrick, T.B. (1997). Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol. Photoimmunol. Photomed. 13, 50-60.
48. Middelkamp-Hup, M.A., Bos, J.D., Rius-Diaz, F., Gonzalez, S., and Westerhof, W. (2007). Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J. Eur. Acad. Dermatol. Venereol. 21, 942-950.